David N. Louis

140.9k citations

322 papers · 75.2k indexed · 19 hit papers · h-index 99

Genetics top 0.01%
Molecular Biology top 0.05%
Pulmonary and Respiratory Medicine top 0.01%
Cancer Research top 0.01%
Oncology top 0.02%

Co-authors: Webster K. Cavenee Otmar D. Wiestler Paul Kleihues Hiroko Ohgaki Andreas von Deimling Guido Reifenberger Peter C. Burger Bernd W. Scheithauer
Topics: Glioma Diagnosis and Treatment (157 papers)Cancer Genomics and Diagnostics (37 papers)Neurofibromatosis and Schwannoma Cases (33 papers)
Cited by: Genetics Cancer Research Neurology
Journals: Science New England Journal of Medicine Proceedings of the National Academy of Sciences
Partner nations: United States Germany Canada

In The Last Decade

David N. Louis

316 papers receiving 73.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

2016 10.9k citations David N. Louis, Arie Perry et al. profile →
The 2007 WHO Classification of Tumours of the Central Nervous System

2007 10.8k citations David N. Louis et al. profile →
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 8.9k citations David N. Louis, Daniel A. Haber et al. profile →
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

2021 6.2k citations David N. Louis, Arie Perry et al. Neuro-Oncology profile →
The 2007 WHO Classification of Tumours of the Central Nervous System

2007 3.5k citations David N. Louis et al. profile →
Erratum to: The 2007 WHO classification of tumours of the central nervous system

2007 3.1k citations David N. Louis et al. profile →
Malignant astrocytic glioma: genetics, biology, and paths to treatment

2007 1.8k citations Robert Bachoo, Keith L. Ligon et al. profile →
The WHO Classification of Tumors of the Nervous System

2002 1.5k citations David N. Louis, Guido Reifenberger et al. Journal of Neuropathology & Experimental Neurology profile →
Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic Oligodendrogliomas

1998 1.2k citations J. Gregory Cairncross, Keisuke Ueki et al. profile →
Human Keratinocytes That Express hTERT and Also Bypass a p16^INK4a-Enforced Mechanism That Limits Life Span Become Immortal yet Retain Normal Growth and Differentiation Characteristics

2000 874 citations David N. Louis et al. profile →
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

2011 739 citations David Capper, Pieter Wesseling et al. profile →
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.

2003 719 citations Catherine L. Nutt, Rebecca A. Betensky et al. PubMed profile →
cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”

2018 553 citations Daniel J. Brat, Kenneth Aldape et al. profile →
MOLECULAR PATHOLOGY OF MALIGNANT GLIOMAS

2006 510 citations David N. Louis profile →
Epidermal growth factor receptor and Ink4a/Arf

2002 501 citations Robert Bachoo, Elizabeth A. Maher et al. profile →
Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma

2011 498 citations Matija Snuderl, Daniel P. Cahill et al. profile →
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations

2013 419 citations Priscilla K. Brastianos, Sandro Santagata et al. profile →
The von Hippel-Lindau Tumor Suppressor Protein Is Required for Proper Assembly of an Extracellular Fibronectin Matrix

1998 395 citations Anat Stemmer‐Rachamimov, David N. Louis et al. profile →
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

2020 310 citations Daniel J. Brat, Kenneth Aldape et al. profile →

Peers

Countries citing papers authored by David N. Louis

Since Specialization

Citations

This map shows the geographic impact of David N. Louis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David N. Louis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David N. Louis more than expected).

Fields of papers citing papers by David N. Louis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David N. Louis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David N. Louis. The network helps show where David N. Louis may publish in the future.

Co-authorship network of co-authors of David N. Louis

This figure shows the co-authorship network connecting the top 25 collaborators of David N. Louis. A scholar is included among the top collaborators of David N. Louis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David N. Louis. David N. Louis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	cIMPACT-NOW update 9: Recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics 2025 ·Neuro-Oncology Advances ·Kenneth Aldape,David Capper,Andreas von Deimling,Caterina Giannini,Mark R. Gilbert,Cynthia Hawkins,Juergen Hench,Thomas S. Jacques,David Jones,David N. Louis,Sabine Mueller,Brent A. Orr,MacLean P. Nasrallah,Stefan M. Pfister,Felix Sahm,Matija Snuderl,David A. Solomon,Pascale Varlet,Pieter Wesseling	9
2	cIMPACT ‐ NOW update 11: Proposal on adaptation of diagnostic criteria for IDH ‐ and H3 ‐wildtype diffuse high‐grade gliomas and for posterior fossa ependymal tumors 2025 ·Brain Pathology ·Pieter Wesseling,David Capper,Guido Reifenberger,Chitra Sarkar,Cynthia Hawkins,Arie Perry,B. K. Kleinschmidt‐DeMasters,Takashi Komori,(unknown),Vani Santosh,Martin J. van den Bent,Michael Weller,Stefan M. Pfister,Uri Tabori,Dominique Figarella‐Branger,Brent A. Orr,David N. Louis	1
3	cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas 2024 ·Neuro-Oncology ·Felix Sahm,Kenneth Aldape,Priscilla K. Brastianos,Daniel J. Brat,Sonika Dahiya,Andreas von Deimling,Caterina Giannini,Mark R. Gilbert,David N. Louis,David R. Raleigh,Guido Reifenberger,Sandro Santagata,Chitra Sarkar,Gelareh Zadeh,Pieter Wesseling,Arie Perry	25
4	cIMPACT‐NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification 2016 ·Brain Pathology ·David N. Louis,Ken Aldape,Daniel J. Brat,David Capper,David W. Ellison,Cynthia Hawkins,Werner Paulus,Arie Perry,Guido Reifenberger,Dominique Figarella‐Branger,Pieter Wesseling,Tracy T. Batchelor,J. Gregory Cairncross,Stefan M. Pfister,Stefan Rutkowski,Michael Weller,Wolfgang Wick,Andreas von Deimling	52
5	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression 2014 ·Cancer Discovery ·James P. Sullivan,Brian V. Nahed,Marissa W. Madden,(unknown),Simeon Springer,Deepak Bhere,S. Andrew,Hiroaki Wakimoto,S. Michael Rothenberg,Lecia V. Sequist,Ravi Kapur,Khalid Shah,A. John Iafrate,William T. Curry,Jay S. Loeffler,Tracy T. Batchelor,David N. Louis,Mehmet Toner,Shyamala Maheswaran,Daniel A. Haber	200
6	Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma 2014 ·Science ·Anoop P. Patel,Itay Tirosh,John J. Trombetta,Alex K. Shalek,Shawn Gillespie,Hiroaki Wakimoto,Daniel P. Cahill,Brian V. Nahed,William T. Curry,R L Martuza,David N. Louis,Orit Rozenblatt–Rosen,Mario L. Suvà,Aviv Regev,B Bernstein	186
7	An Aberrant Transcription Factor Network Essential for Wnt Signaling and Stem Cell Maintenance in Glioblastoma 2013 ·Cell Reports ·Esther Rheinbay,Mario L. Suvà,Shawn Gillespie,Hiroaki Wakimoto,Anoop P. Patel,Mohd Shahid,Ozgur Oksuz,Samuel D. Rabkin,Robert L. Martuza,Miguel N. Rivera,David N. Louis,Simon Kasif,S. Andrew,B Bernstein	197
8	An Ultra-High Speed Whole Slide Image Viewing System 2012 ·Analytical Cellular Pathology ·Yukako Yagi,(unknown),(unknown),Maristela L. Onozato,(unknown),Kiyoshi Osato,(unknown),Eugene J. Mark,Matthew P. Frosch,David N. Louis	17
9	Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma 2010 ·Journal of Clinical Oncology ·Tracy T. Batchelor,Dan G. Duda,Emmanuelle di Tomaso,Marek Ancukiewicz,Scott R. Plotkin,Elizabeth R. Gerstner,April F. Eichler,Jan Drappatz,Fred H. Hochberg,Thomas Benner,David N. Louis,Kenneth S. Cohen,(unknown),(unknown),Jay S. Loeffler,Marsha A. Moses,Percy Ivy,A. Gregory Sorensen,Patrick Y. Wen,Rakesh K. Jain	406
10	MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance 2009 ·Clinical Cancer Research ·Stephen Yip,Jiangyong Miao,Daniel P. Cahill,A. John Iafrate,Ken Aldape,Catherine L. Nutt,David N. Louis	292
11	Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment 2007 ·Clinical Cancer Research ·Daniel P. Cahill,Kymberly K. Levine,Rebecca A. Betensky,Patrick J. Codd,Candice A. Romany,Linsey B. Reavie,Tracy T. Batchelor,P. Andrew Futreal,Michael R. Stratton,William T. Curry,A. John Iafrate,David N. Louis	330
12	Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant Glioma 2007 ·Neuron ·Keith L. Ligon,Emmanuelle Huillard,Shwetal Mehta,Santosh Kesari,Hongye Liu,John A. Alberta,Robert Bachoo,Michael Kane,David N. Louis,Ronald A. DePinho,David J. Anderson,Charles D. Stiles,David H. Rowitch	378
13	AKT Activation in Human Glioblastomas Enhances Proliferation via TSC2 and S6 Kinase Signaling 2006 ·Cancer Research ·Markus J. Riemenschneider,Rebecca A. Betensky,(unknown),David N. Louis	110
14	Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities 2006 ·Cancer Research ·Elizabeth A. Maher,Cameron Brennan,Patrick Y. Wen,Laura Durso,Keith L. Ligon,Aaron Richardson,Deepak Khatry,Bin Feng,Raktim Sinha,David N. Louis,John Quackenbush,Peter McL. Black,Lynda Chin,Ronald A. DePinho	140
15	Autocrine Platelet-Derived Growth Factor–Dependent Gene Expression in Glioblastoma Cells Is Mediated Largely by Activation of the Transcription Factor Sterol Regulatory Element Binding Protein and Is Associated with Altered Genotype and Patient Survival in Human Brain Tumors 2005 ·Cancer Research ·Deqin Ma,Catherine L. Nutt,(unknown),Xuejun Peng,David N. Louis,David M. Kaetzel	27
16	CD155/PVR plays a key role in cell motility during tumor cell invasion and migration 2004 ·BMC Cancer ·(unknown),Brenda K. Eustace,Jean K. Stewart,(unknown),(unknown),(unknown),Jennifer E. Roy,Christine Unger,David N. Louis,Leodevico L. Ilag,Daniel G. Jay	202
17	BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. 2003 ·PubMed ·Kristina Braaten,Rebecca A. Betensky,Laurence de Leval,Yoshifumi Okada,Fred H. Hochberg,David N. Louis,Nancy L. Harris,Tracy T. Batchelor	145
18	Universal absence of merlin, but not other ERM family members, in schwannomas. 1997 ·PubMed ·Anat Stemmer‐Rachamimov,Lin Xu,Charo Gonzalez-Agosti,(unknown),Denise Pinney,Roberta L. Beauchamp,(unknown),James F. Gusella,Vijaya Ramesh,David N. Louis	93
19	Malignant Astrocytomas with Homozygous CDKN2/p16 Gene Deletions Have Higher Ki-67 Proliferation Indices 1996 ·Journal of Neuropathology & Experimental Neurology ·Yasuhiro Ono,Takashi Tamiya,Tomotsugu Ichikawa,(unknown),Kengo Matsumoto,Tomohisa Furuta,Takashi Ohmoto,Keisuke Ueki,David N. Louis	4
20	Malignant Astrocytomas with Homozygous CDKN2/p16 Gene Deletions Have Higher Ki-67 Proliferation Indices 1996 ·Journal of Neuropathology & Experimental Neurology ·Yasuhiro Ono,Takashi Tamiya,Tomotsugu Ichikawa,(unknown),Kengo Matsumoto,Tomohisa Furuta,Takashi Ohmoto,Keisuke Ueki,David N. Louis	75

About David N. Louis

David N. Louis is a scholar working on Genetics, Neurology and Cancer Research, having authored 322 papers that have together received 75.2k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (157 papers), Cancer Genomics and Diagnostics (37 papers) and Neurofibromatosis and Schwannoma Cases (33 papers). The work is most often cited by research in Genetics (37.3k citations), Cancer Research (17.0k citations) and Neurology (13.1k citations). David N. Louis has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Webster K. Cavenee, Otmar D. Wiestler, Paul Kleihues, Hiroko Ohgaki, Andreas von Deimling, Guido Reifenberger, Peter C. Burger, Bernd W. Scheithauer, Anne Jouvet and Arie Perry. Their work appears in journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact